NEWARK, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that management will participate in two investor conferences including the Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York City and the Evercore ISI 2nd Annual HEALTHCONx Conference in Boston, MA – December 3-5, 2019.
|Stifel 2019 Healthcare Conference|
|Date:||Tuesday, November 19|
|Time:||8:00am Eastern Time|
|Evercore ISI 2nd Annual HEALTHCONx Conference|
|Date:||Tuesday, December 3|
|Time:||11:45am Eastern Time|
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay’s lead development candidate, seladelpar, is a potent, selective and orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). CymaBay is evaluating seladelpar in a global, Phase 3 registration study in PBC, a Phase 2 dose ranging study in PSC and a Phase 2b dose ranging study in NASH.
For additional information about CymaBay visit www.cymabay.com.
LifeSci Advisors, LLC